Vonsetamig
Unknown / undisclosed
Also known as REGN5459
Evidence outlook · no controlled comparison
NCT04083534 · Relapsed Multiple Myeloma, Refractory Multiple Myeloma
The lead study produced no formal comparison against a control: it had a single arm, or its primary endpoint did not compare the groups (for example, a safety count). This tier describes the design, not an outcome.
NCT04083534: This early-stage study gave REGN5459 to 43 people with relapsed or refractory multiple myeloma across a range of doses, with no randomisation, no masking and no comparison group. Its primary measure was dose-limiting toxicity: one such event occurred, a grade 3 drop in blood oxygen at the highest 900 mg dose, the maximum tolerated dose was not reached, and 480 mg was chosen for later study. A study of this shape shows which doses are tolerated, not whether the drug works better than an alternative.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Also in development:Systemic Lupus Erythematosus · Phase 1Lupus Nephritis · Phase 1
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04083534 NCT04083534 · Relapsed Multiple Myeloma, Refractory Multiple Myeloma This early-stage study gave REGN5459 to 43 people with relapsed or refractory multiple myeloma across a range of doses, with no randomisation, no masking and no comparison group. Its primary measure was dose-limiting toxicity: one such event occurred, a grade 3 drop in blood oxygen at the highest 900 mg dose, the maximum tolerated dose was not reached, and 480 mg was chosen for later study. A study of this shape shows which doses are tolerated, not whether the drug works better than an alternative. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT04083534 | 1/2 | Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period (Up to 35 Days); Incidence and severity of treatment-emergent adverse events (TEAEs) during REGN5459 treatment period (Up to 12 Weeks After the Last Dose); Incidence and severity of adverse events of special interest (AESI) with REGN5459 treatment period (Up to 12 Weeks After the Last Dose); Objective response rate (ORR) as measured using the International Myeloma Working Group (IMWG) criteria (Up to Approximately 104 Weeks) 2025-05-01 | Dose-limiting toxicity incidence across the dose-escalation range (3-900 mg): 1 DLT observed in 43 enrolled patients, at the 900 mg dose level (grade 3 hypoxia); maximum tolerated dose not reached, 480 mg selected as the recommended phase 2 dose. | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (2)
What this study did
What this study did
Phase 1 (1)
What this study did
Competitive landscape
Other BCMA x CD3 drugs
Elranatamab, Linvoseltamab, Teclistamab, Etentamig, F182112 and 6 more. Compare all 12 BCMA x CD3 drugs
This mechanism is crowded: 11 other tracked programmes target it, 10 of them ahead of this one.
This drug's own stage for Lupus Nephritis: Phase 1. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Vonsetamig: this drug | Phase 1 | — | BCMA x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Belimumab (GSK1550188) (Benlysta) | Approved | Monoclonal antibody | BAFF / BLyS (B-lymphocyte stimulator), BAFF (BLyS) | Reliable signal | No reviewed efficacy summary in this indication | |
| Obinutuzumab | Approved | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Repository Corticotropin (Acthar Gel) | Approved | Peptide | Melanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Voclosporin (Lupkynis) | Approved | Small molecule | Calcineurin, Cyclophilin A (leading to calcineurin inhibition) | Reliable signal | NCT03021499: Number of Participants With Adjudicated Renal Response at Week 52 (52 Weeks): Voclosporin — Number of renal responders: 73/179 (40.8%); Number of renal non-responders: 106/179 (59.2%) vs Placebo Oral Capsule — Number of renal responders: 40/178 (22.5%); Number of renal non-responders: 138/178 (77.5%) | |
| Ebribafusp Alfa | Phase 2 | Protein / enzyme therapeutic | C3d / Factor H | not yet graded | No reviewed efficacy summary in this indication | |
| Rapcabtagene Autoleucel | Phase 2 | Undisclosed | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-2173 | Phase 2 | Undisclosed | IFNAR1 / TACI | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
4 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Vonsetamig to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.